Long-term (LT) Exposure to low-dose prednisone given with or without abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients

被引：0

作者：

Ryan, Charles J. ^{[1
]}

Chi, Kim N. ^{[2
]}

de Bono, Johann S. ^{[3
,4
]}

Fizazi, Karim ^{[5
]}

Gomella, Leonard G. ^{[6
,7
]}

Miller, Kurt ^{[10
]}

Rathkopf, Dana E. ^{[8
,9
,11
]}

Scher, Howard I. ^{[6
,7
]}

Shore, Neal D. ^{[10
]}

De Porre, Peter ^{[8
,9
,11
]}

Londhe, Anil ^{[8
,9
,11
]}

McGowan, Tracy ^{[12
]}

Pelhivanov, Nonko ^{[8
,9
,11
]}

Charnas, Robert ^{[8
,9
,11
]}

Todd, Mary B. ^{[13
]}

Montgomery, Bruce ^{[14
]}

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[2] BC Canc Agcy, Vancouver, BC, Canada

[3] Inst Canc Res, London, England

[4] Univ Paris 11, Inst Gustave Roussy, Paris, France

[5] Univ Paris 11, Inst Gustave Roussy, Paris, France

[6] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA

[7] Charite Univ Med Berlin, Berlin, Germany

[8] Mem Sloan Kettering Canc Ctr, New York, NY USA

[9] Weill Cornell Med Coll, New York, NY USA

[10] Atlantic Urol Clin, Carolina Urol Res Ctr, Panama City, Panama

[11] Janssen Res & Dev, London, England

[12] Janssen Sci Affairs, London, England

[13] Janssen Global Serv, Titusville, NJ USA

[14] Univ Washington, Seattle, WA 98195 USA

来源：

BJU INTERNATIONAL | 2015年 / 116卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

118

引用

页码：15 / 15

页数：1

共 50 条

[1] Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).
Fizazi, Karim
Chi, Kim N.
De Bono, Johann Sebastian
Gomella, Leonard G.
Miller, Kurt
Rathkopf, Dana E.
Ryan, Charles J.
Scher, Howard I.
Shore, Neal D.
De Porre, Peter
Londhe, Anil
McGowan, Tracy
Pehlivanov, Nonko
Charnas, Robert Louis
Todd, Mary Beth
Montgomery, Robert B.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[2] ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS)
Gomella, Leonard G.
Chi, Kim N.
de Bono, Johann S.
Fizazi, Karim
Miller, Kurt
Rathkopf, Dana E.
Ryan, Charles J.
Scher, Howard I.
Shore, Neal D.
De Porre, Peter
Londhe, Anil
McGowan, Tracy
Pelhivanov, Nonko
Charnas, Robert
Todd, Mary B.
Montgomery, Bruce
[J]. JOURNAL OF UROLOGY, 2015, 193 (04): : E1091 - E1091
[3] Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer
Fizazi, Karim
Chi, Kim N.
de Bono, Johann S.
Gomella, Leonard G.
Miller, Kurt
Rathkopf, Dana E.
Ryan, Charles J.
Scher, Howard I.
Shore, Neal D.
De Porre, Peter
Londhe, Anil
McGowan, Tracy
Pelhivanov, Nonko
Charnas, Robert
Todd, Mary B.
Montgomery, Bruce
[J]. EUROPEAN UROLOGY, 2016, 70 (03) : 438 - 444
[4] Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302)
Rathkopf, Dana E.
Smith, Matthew R.
De Bono, Johann Sebastian
Logothetis, Christopher
Shore, Neal
De Souza, Paul L.
Fizazi, Karim
Mulders, Peter
Mainwaring, Paul N.
Hainsworth, John D.
Beer, Tomasz M.
North, Scott A.
Fradet, Yves
Griffin, Thomas W.
Park, Youn Choi
Kheoh, Thian San
Small, Eric Jay
Scher, Howard I.
Molina, Arturo
Ryan, Charles J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[5] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Auchus, Richard J.
Yu, Margaret K.
Nguyen, Suzanne
Mundle, Suneel D.
[J]. ONCOLOGIST, 2014, 19 (12): : 1231 - 1240
[6] Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC)
Slovin, Susan F.
Knudsen, Karen E.
Halabi, Susan
Fleming, Mark T.
Molina, Ana M.
Wolf, Steven Paul
de Leeuw, Renee
Fernandez, Celina
Kang, Praneet
Southwell, Traci
Jones, Carol L.
Fernandez, Escarleth
Kelly, William Kevin
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[7] Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA plus P) for ≥ 4 years (yrs)
Carles, J.
Davis, I.
De Bono, J. S.
Fizazi, K.
Gerritsen, W.
Rathkopf, D. E.
Ryan, C. J.
Saad, F.
Steuber, T.
Wilding, G.
Park, Y. C.
Charnas, R.
De Porre, P.
Van Poppel, H.
[J]. ANNALS OF ONCOLOGY, 2016, 27
[8] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
Rathkopf, Dana E.
Antonarakis, Emmanuel S.
Shore, Neal D.
Tutrone, Ronald
Alumkal, Joshi J.
Ryan, Charles J.
Saleh, Mansoor N.
Hauke, Ralph J.
Bandekar, Rajesh
Maneval, Edna Chow
de Boer, Carla
Todd, Mary
Yu, Margaret K.
Scher, Howard I.
[J]. CANCER RESEARCH, 2014, 74 (19)
[9] Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone
Duarte, C.
Jimeno, A.
Kessler, E. R.
[J]. DRUGS OF TODAY, 2019, 55 (01) : 5 - 15
[10] Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Posadas, Edwin M.
Chit, Kim N.
de Wit, Ronald
de Jonge, Maja J. A.
Attard, Gerhardt
Friedlander, Terence
Yu, Margaret
Hellemans, Peter
Chien, Caly
Abrams, Charlene
Gonzalez, Martha
Trudel, Geralyn C.
Chauhan, Vijay
Saad, Fred
[J]. CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 →